Work

Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.9568

Authors: Fiona Taylor, Meredith M. Regan, Dirk Schadendorf, Michael B. Atkins, Rachael Lawrance, Alejandro Moreno-Koehler, Andriy Moshyk, Sumati Rao, Corey Ritchings, SRIVIDYA KOTAPATI, Jennifer Lord-Bessen, Jasmine I. Rizzo, David F. McDermott, Mark R. Middleton

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Duisburg-Essen, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Adelphi Group (United Kingdom), Bristol-Myers Squibb (United States), Beth Israel Deaconess Medical Center, University of Oxford

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947930698

Cites:

Cited by:

Related to: 10